Arcutis Biotherapeutics, Inc.
NMS: ARQTLive Quote
📈 ZcoreAI Score
Our AI model analyzes Arcutis Biotherapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ARQT Z-Score →About Arcutis Biotherapeutics, Inc.
Healthcare
Biotechnology
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
📊 Fundamental Analysis
Arcutis Biotherapeutics, Inc. demonstrates a profit margin of -4.3%, which is below the sector average, suggesting competitive pressure.
The company recently reported 81.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -9.3%, which indicates that capital utilization is currently under pressure.
At a current price of $24.21, ARQT currently sits at the 61st percentile of its 52-week range (Range: $12.42 - $31.77).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$3.00B
Trailing P/E
--
Forward P/E
18.94
Beta (5Y)
1.77
52W High
$31.77
52W Low
$12.42
Avg Volume
1.32M
Day High
Day Low